Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

Median progression-free survival was 13.2 months with Enhertu, compared to 8.1 months in the chemotherapy arm. The trial also indicated that HER2-ultralow patients responded similarly to those in ...

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in damages, in an ongoing ...

Median progression-free survival was 13.2 months with Enhertu compared with 8.1 months with chemotherapy. “The recent approval for Enhertu in patients that have HR-positive, and HER2-low or -ultralow ...

Also, treatment with Enhertu in patients with HER2-low expression led to progression-free survival (PFS) of 13.2 months as compared to 8.1 months for chemotherapy. This was the primary endpoint of ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast ... six months of life – from 16.8 months to 23.4 months – a result that ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...

Roche’s PATHWAY test was used in Enhertu’s DESTINY-Breast06 clinical trial, which demonstrated a median progression-free survival of 13.2 months with the antibody-drug conjugate compared to 8. ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...